Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab

Clinical Cancer Research

Volumn 23, Issue 24, 2017, Pages 7498-7511

  Krejcik, Jakub ^a,b   Frerichs, Kris A ^a   Nijhof, Inger S ^a   Van Kessel, Berris ^a   Van Velzen, Jeroen F ^c   Bloem, Andries C ^c   Broekmans, Marloes E C ^a   Zweegman, Sonja ^a   Van Meerloo, Johan ^a   Musters, Rene J P ^d   Poddighe, Pino J ^a   Groen, Richard W J ^a   Chiu, Christopher ^e   Plesner, Torben ^b   Lokhorst, Henk M ^a   Kate Sasser, A ^e   Mutis, Tuna ^a   Van De Donk, Niels W C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; CD38 ANTIGEN; CD56 ANTIGEN; DARATUMUMAB; DEXAMETHASONE; IMMUNOGLOBULIN G; LENALIDOMIDE; SYNDECAN 1; ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; MONOCLONAL ANTIBODY; THALIDOMIDE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CELL MEMBRANE; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EFFECTOR CELL; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MONOCYTE; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PHENOMENA AND FUNCTIONS OF BIOLOGICAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEPLETION; T LYMPHOCYTE; TREATMENT DURATION; TROGOCYTOSIS; YOUNG ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TUMOR CELL LINE;

ADP-RIBOSYL CYCLASE 1; AGED; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CELL LINE, TUMOR; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTES; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE MYELOMA; T-LYMPHOCYTES; THALIDOMIDE;

EID: 85038600602     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-2027     Document Type: Article

References (50)

1. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207–19.
2. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551–60.
3. Nijhof IS, Groen RW, Noort WA, van KB, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2015;21:2802–10.
4. Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 2016;128:1821–8.
5. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319–31.
6. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754–66.
7. Overdijk MB, Verploegen S, Bogels M, van EM, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015;7:311–21.
8. Nijhof IS, Lammerts van Bueren JJ, van KB, Andre P, Morel Y, Lokhorst HM, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 2015;100:263–8.
9. de Weers M, Tai YT, van d V, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840–8.
10. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–27.
11. Jansen JHM, Boross P, Overdijk MB, van Bueren JJL, Parren PWHI, Leusen JH. Daratumumab, a Human CD38 antibody induces apoptosis of myeloma tumor cells via fc receptor-mediated crosslinking. ASH Annual Meeting Abstracts 2012;120:2974.
12. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38þ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016;128: 384–94.
13. Nijhof IS, Casneuf T, van VJ, van KB, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 2016;128:959–70.
14. Nijhof IS, Groen RW, Lokhorst HM, van KB, Bloem AC, van VJ, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 2015;29: 2039–49.
15. Boxhammer R, Steidl S, Endell J. Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide. J Clin Oncol 2015;33; 8588.
16. Endell J, Boxhammer R, Steidl S. Synergistic in vitro activity of MOR202, a human CD38 antibody, in combination with pomalidomide. Blood 2014;124:5712.
17. van der Spek E, Bloem AC, Lokhorst HM, van KB, Bogers-Boer L, van de Donk NW. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2009;33:100–8.
18. Casneuf T, Xu X, Adams H, Axel A, Verbist B, Liu K, et al. Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed/refractory multiple myeloma. Haematologica 2016;p B18.
19. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231–42.
20. Nijhof IS, Groen RW, Noort WA, van KB, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2015;21:2802–10.
21. van de Veer M, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96: 284–90.
22. DARZALEX (daratumumab) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc; 2016.
23. Adams H, Stevenaert F, Krejcik J, van der Borcht K, Casneuf T, Smets T, et al. High-parameter mass cytometry (CyTOF) evaluation of relapsed/ refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism of action. Blood 2016;128:4521.
24. Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood 2017;129:3033–7.
25. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011;154:216–22.
26. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 2012;26: 1301–12.
27. Vaisitti T, Serra S, Pepper C, Rossi D, Laurenti L, Gaidano G, et al. CD38 signals upregulate expression and functions of matrix metal-loproteinase-9 in chronic lymphocytic leukemia cells. Leukemia 2013;27:1177–81.
28. Deaglio S, Vaisitti T, Billington R, Bergui L, Omede' P, Genazzani AA, et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 2007;109:5390–8.
29. Valgardsdottir R, Cattaneo I, Klein C, Introna M, Figliuzzi M, Golay J. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. Blood 2017;129: 2636–44.
30. Taylor RP, Lindorfer MA. Fcgamma-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 2015;125:762–6.
31. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003;4:815.
32. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood 2013;122:3020–9.
33. Zhang Y, McClellan M, Efros L, Shi D, Bielekova B, Tang MT, et al. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis. Mult Scler 2014;20:156–64.
34. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916–24.
35. Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum 2012;64:3111–8.
36. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600–9.
37. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435–43.
38. Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, et al. Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res 2016;22:5211–22.
39. Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med 2013; 19:99–108.
40. Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, et al. CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting auto-logous CD4þ T cell proliferation. J Immunol 2015;195:965–72.
41. Horenstein AL, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V, et al. Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Mol Med 2016;22.
42. Chen L, Averett Byers L, Ullrich S, Wistuba I, Qin X, Gibbons D. CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis. J Clin Oncol 2017;35:79.
43. An G, Jiang H, Acharya C, Zhong MY, Cai T, Yang G, et al. SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma. Blood 2014;124:4729.
44. Velmurugan R, Challa DK, Ram S, Ober RJ, Ward ES. Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. Mol Cancer Ther 2016;15:1879–89.
45. Taylor RP, Lindorfer MA. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol 2014;86:485–91.
46. Pham T, Mero P, Booth JW. Dynamics of macrophage trogocytosis of rituximab-coated B cells. PLoS One 2011;6:e14498.
47. Griffin FM Jr, Griffin JA, Silverstein SC. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med 1976; 144:788–809.
48. Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, et al. NAD(þ)-Metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model. Cells 2015;4:520–37.
49. Chillemi A, Quarona V, Zito A, Morandi F, Marimpietri D, Cuccioloni M, et al. Generation and characterization of microvesicles after daratumumab interaction with myeloma cells. Blood 2015;126:1849.
50. Alici E, Chrobok M, Lund J, Ahmadi T, Khan I, Duru AD, et al. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol 2016; 174:473–7.